JMML with a somatic KRAS mutation and monosomy 7 has been found to respond well to 5-azacitidine in other reports as well, suggesting this may be a population of JMML patients who can be cured with 5-azacitidine alone, though additional study is needed [22,30,31,32]. Here, KRAS is linked to juvenile myelomonocytic leukemia.